Almac Group Announces Support of Agios' PYRUKYND®
Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).
The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK deficiency, a rare, debilitating, and lifelong form of anemia.
Read more about the work between Almac Group and Agios here.
Recent Videos
Related Content
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Podcast
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
